Last reviewed · How we verify

Cholecalciferol 12 000 UI — Competitive Intelligence Brief

Cholecalciferol 12 000 UI (Cholecalciferol 12 000 UI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D supplement. Area: Nutritional deficiency / Bone health.

marketed Vitamin D supplement Vitamin D receptor (VDR) Nutritional deficiency / Bone health Small molecule Live · refreshed every 30 min

Target snapshot

Cholecalciferol 12 000 UI (Cholecalciferol 12 000 UI) — Assistance Publique - Hôpitaux de Paris. Cholecalciferol (vitamin D3) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cholecalciferol 12 000 UI TARGET Cholecalciferol 12 000 UI Assistance Publique - Hôpitaux de Paris marketed Vitamin D supplement Vitamin D receptor (VDR)
Vitamin D3 tablets Vitamin D3 tablets Ain Shams University marketed Vitamin D supplement / Secosteroid Vitamin D receptor (VDR)
oral cholecalciferol + life style counselling oral cholecalciferol + life style counselling Post Graduate Institute of Medical Education and Research, Chandigarh marketed Vitamin D supplement Vitamin D receptor (VDR)
Cholecalciferol (vitamin D) Cholecalciferol (vitamin D) University of Tromso marketed Vitamin D supplement / Secosteroid Vitamin D receptor (VDR)
Ergocalciferol 50000 UNT Ergocalciferol 50000 UNT University of Alabama at Birmingham marketed Vitamin D supplement Vitamin D receptor (VDR)
ergocalciferol (vitamin D2) ergocalciferol (vitamin D2) Atlanta VA Medical Center marketed Vitamin D supplement Vitamin D receptor (VDR)
D3 vitamin D3 vitamin Medical University of Lodz marketed Vitamin D supplement / Secosteroid Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D supplement class)

  1. Hospices Civils de Lyon · 2 drugs in this class
  2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  3. Atlanta VA Medical Center · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. Centre of Postgraduate Medical Education · 1 drug in this class
  6. Hospital Infantil de Mexico Federico Gomez · 1 drug in this class
  7. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
  8. University Hospital, Tours · 1 drug in this class
  9. University of Alabama at Birmingham · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cholecalciferol 12 000 UI — Competitive Intelligence Brief. https://druglandscape.com/ci/cholecalciferol-12-000-ui. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: